Mesa Labs' New CEO Breaks Silence: Execution, Not Demand, Is the Problem
100-day review reveals delivery reliability issues, doubles down on BPD platform and deleveraging
MLAB · Earnings Call · 2026-08-10
A Direct First Date
Mesa Laboratories (MLAB) reported fiscal first-quarter results on August 10, 2026, but the real story is the tone set by incoming CEO Siddhartha Kadia in his first earnings call. Kadia spent his opening minutes explaining that he didn't write a vision statement—he traveled to every site with more than 25 employees and met with over half the company. “I did not spend my first 100 days writing a vision statement. I spent them inside the company.” — Siddhartha Kadia, CEO · 2026-08-10 That directness is a deliberate break from the prior administration's more acquisitive posture, and it frames everything else on the call.
The numbers for the quarter were mixed but directionally positive: total revenue grew 1% organically, adjusted operating income jumped 19.5% (excluding a legal settlement), and gross margin expanded to 66.2% (up ~400 bps). The headline, however, was the diagnosis of the Sterilization and Disinfection Controls (SDC) franchise, which reported a 3.6% organic revenue decline. Kadia was unambiguous: “This is a delivery reliability problem. it is not a demand problem.” — Siddhartha Kadia, CEO · 2026-08-10 He walked through the mechanics—past-due backlog built in fiscal 2025, was cleared in bursts, then rose again in the first quarter. The fix, he said, is standard work and process discipline, not capacity; delivery reliability is the new watchword. The market seemed to agree: MLAB shares rose ~10.6% in the eight days following the report.
The BPD Turnaround and the Gyrolab Catalyst
The more compelling story is in Biopharmaceutical Development (BPD). After a disastrous -30% quarter a year ago, BPD posted +5% organic growth this quarter. Kadia cautioned against victory laps—call it “catch-up” rather than a completed turnaround—but he revealed a strategic decision that could reset the franchise's growth ceiling: a next-generation Gyrolab platform is now targeted for launch in fiscal 2028. “We have a next-generation platform in development… we now expect the new Gyrolab platform to launch in fiscal 2028.” — Siddhartha Kadia, CEO · 2026-08-10 This is the clearest signal of the operating tempo he intends to run. He also highlighted (in Q&A) that he brought in a new general manager for BPD and is rebuilding the commercial engine from the ground up.
Coupled with the SDC narrative, the portfolio message is coherent: three of four franchises are durable, regulation-embedded, and growing on a trailing-twelve-month basis; the fourth (Clinical Genomics) is being deliberately managed as a declining but cash-generative asset. Kadia described his priority as “self-help” rather than disciplined capital allocation toward acquisitions—at least for now. The balance sheet supports this: net leverage stands at 1.85x, down from 2.0x a year ago, and the company paid down $8.7M of debt in the quarter. Management targets 1.5–1.75x by year-end.
Financial Discipline and the Path to Guidance
The first quarter is structurally the lightest volume quarter, and the company delivered a 25.6% adjusted operating margin (excluding unusual items) — a strong print that CFO John Sakys warned not to annualize. The gross margin expansion came from supply-chain efficiencies and favorable mix in BPD, Calibration Solutions (+7.6% organic growth), and Clinical Genomics, which more than offset SDC's volume drag. Gross margin rose to 66.2% from 62.0% a year ago, a 420 bp jump that underscores the operating leverage in the business. Free cash flow also aided the balance sheet, as operating cash flow jumped $12.8M year-over-year.
Kadia reiterated his commitment to full-year fiscal 2027 guidance at the November call, when first-half results are in. He explicitly declined to offer interim guidance, but laid out a simple promise: “we are not going to provide any color on the guidance itself right now.” — Siddhartha Kadia, CEO · 2026-08-10 That restraint—combined with the directness about execution failures—is refreshing for a small-cap (market cap ≈ $575M) that historically leaned on M&A for growth.
The loyal customers theme emerged repeatedly. Kadia framed them as the company's most valuable asset, and the SDC apology was about not breaking promises to them. organic revenue is now the metric investors should track, not quarter-to-quarter gyrations in SDC, he argued.
Bottom Line
This is a classic “new CEO reset” story, but with substance. The SDC diagnosis is refreshingly honest—and the fact that the company is not loosening quality standards to ship faster is the right long-term trade-off. The BPD platform launch in fiscal 2028 is a multi-year catalyst that could re-rate the stock. Add in the path of steady deleveraging, and the near-term risk/reward favors execution over acquisition. The fall call will be the real test: delivery reliability improvements must show up in trailing-twelve-month numbers, and the promised full-year guidance will need to be credible. If Kadia's directness is more than rhetoric, this could be the start of a healthy re-rating.